Lexicon Pharmaceuticals (LXRX) Other financing activities (2012 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Other financing activities of $65000.0 for Q1 2026, up 6600.0% quarter-over-quarter from -$1000.0 in Q4 2024.
Lexicon Pharmaceuticals (LXRX) Other financing activities (2012 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Other financing activities for 10 consecutive years, with $65000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $65000.0; the TTM figure through Mar 2026 stood at $65000.0 (up 104.66% YoY), while the FY2024 annual figure was -$1.3 million, changed N/A from the prior year.
- Other financing activities grew to $65000.0 in Q1 2026 per LXRX's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $94.3 million in Q3 2022 and bottomed at -$906000.0 in Q3 2024.
- Historically, Other financing activities has averaged $9.3 million across 4 years, with a median of $32000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other financing activities jumped 392.96% — and 2024, when it slumped 258.96%.
- Lexicon Pharmaceuticals' Other financing activities stood at -$698000.0 in 2022, then soared by 56.02% to -$307000.0 in 2023, then jumped by 99.67% to -$1000.0 in 2024, then jumped by 6600.0% to $65000.0 in 2026.
- Business Quant data shows LXRX's Other financing activities at $65000.0 in Q1 2026, -$1000.0 in Q4 2024, and -$906000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.34 Mn |
| Jun 30, 2026 | -2.34 Mn |
| Mar 31, 2026 | 65,000.00 |
| Mar 31, 2026 | 65,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -906,000.00 |
| Sep 30, 2024 | -906,000.00 |
| Jun 30, 2024 | -488,000.00 |
| Jun 30, 2024 | -488,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Sep 30, 2023 | -307,000.00 |
| Sep 30, 2023 | -307,000.00 |
| Jun 30, 2023 | 307,000.00 |
| Jun 30, 2023 | 307,000.00 |
| Dec 31, 2022 | -698,000.00 |
| Dec 31, 2022 | -698,000.00 |
| Sep 30, 2022 | 94.27 Mn |
| Sep 30, 2022 | 94.27 Mn |